Lonza acquiring smaller peptide players, or Carlyle investing in Bachem) to capture GLP-1 growth ( [50] ) ( [13] )
Visible wellbeing should look calm and steady, not edgy or unsettled
Melting curve analysis was performed to confirm the production of a single product in each reaction
April 1, 2026: More Lawsuits Join Vision Loss MDL for GLP-1 Drugs, Like Ozempic As of April 1, 2026, there are 73 pending lawsuits in the centralized litigation for people alleging NAION from GLP-1 drugs, including Ozempic
When used responsibly and consistently, they can be a useful addition to a thoughtful skincare and wellness routine, supporting brighter, healthier-looking skin over time rather than chasing instant results